Bioventus amends CartiHeal acquisition, defers $215M upfront, lowers sales milestone to $75M

Bioventus Inc.

Deferred $215M of $315M upfront; paid in five tranches 2023–2027 with 8% annual interest.
Contingent ~$135M now triggered at $75M trailing sales (down from $100M).
Expected close by end of July 2022; upfront ~$100M (incl. $50M escrowed).
Bioventus to pay ~$8M of CartiHeal's transaction fees.
Additional milestones: First Paper $50M, Additional Publication $25M, etc., with interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.